Protara Therapeutics
TARA
28 hedge funds and large institutions have $92.3M invested in Protara Therapeutics in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 5 closing their positions.
3,081% more capital invested
Capital invested by funds: $2.9M → $92.3M (+$89.4M)
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
75% more funds holding
Funds holding: 16 → 28 (+12)
66.93% more ownership
Funds ownership: 0.76% → 67.7% (+67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$64.2M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$12.9M |
| 3 |
DM
Deerfield Management
New York
|
+$11.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$5.82M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$5.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$140K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$84K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$63K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$6K |
TARA Hedge Fund Activity: Q1 2020 in Review
28 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2020, worth a combined $92.3M — up 3,081% from $2.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TARA positions and 5 closed out — a net gain of 12 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was Opaleye Management, adding an estimated $64.2M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $140K sold.
- 28 institutional investors held Protara Therapeutics (TARA) as of Q1 2020, up from 16 in Q4 2019.
- Funds reported $92.3M of Protara Therapeutics stock for Q1 2020, up 3,081% quarter-over-quarter.
- 17 funds opened new Protara Therapeutics positions in Q1 2020 and 5 closed out, a net change of +12 holders.
- The largest Protara Therapeutics buyer in Q1 2020 was Opaleye Management, an estimated $64.2M added.
- The largest Protara Therapeutics seller in Q1 2020 was Fairmount Funds Management, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2020.